Expressions and clinical significances of Hepcidin, BMP6 and HJV in gastric cancer

Abstract

Abstract:Objective To study the expressions of Hepcidin, bone morphogenetic protein 6 (BMP6) and hemojuvelin (HJV) in gastric cancer, and to explore their relationships with clinical pathological characte-ristics. Methods Hepcidin, BMP6 and HJV were detected by immunohistochemistry in 62 cases of gastric cancer patients, and the relationships among them and clinical pathological features were analyzed. Results Compared with normal gastric mucosa tissues, Hepcidin was highly expressed in gastric cancer tissues (13.3%vs.56.5%,χ²=8.99，P＜0.01), while the differences of the expression of BMP6 and HJV in the two groups were not statistically significant (60.0%vs.40.3%,χ²=1.89,P＞0.05; 93.3%vs.83.9%,χ²=0.88,P＞0.05). The expression of Hepcidin was related to T stage (χ²=6.98,P=0.02), but it was not related to age, sex, lymph node metastasis, distant metastasis and anemia. The expressions of BMP6 and HJV were not related to T stage, age, sex, lymph node metastasis, distant metastasis and anemia. Hepcidin was not related to the expressions of BMP6 and HJV (r=0.13,P＞0.05;r=0.15,P＞0.05). Conclusion Hepcidin is highly expressed in gastric cancer tissues, which is related to the T staging of gastric cancer, and can be used as an objective indicator of the biological behavior of gastric cancer. There were no differences in the expression of BMP6 and HJV between normal gastric mucosa and gastric cancer tissues.

Key words:Stomach neoplasms,Anemia,Bone morphogenetic proteins,Hepcidin,Hemojuvelin

Li Rong, Lu Ye, Cheng Xu, Yan Min, Pan Xiangtao. Expressions and clinical significances of Hepcidin, BMP6 and HJV in gastric cancer[J]. Journal of International Oncology, 2016, 43(3): 180-183.

References

［1］ Alkhateeb AA, Connor JR. The significance of ferritin in cancer: antioxidation, inflammation and tumorigenesis［J］. Biochim Biophys Acta, 2013, 1836(2): 245-254. DOI: 10.1016/j.bbcan.2013.07.002. ［2］ Vanderwall K, Daniels-Wells TR, Penichet M, et al. Iron in multiple myeloma［J］. Crit Rev Oncog, 2013, 18(5): 449-461. ［3］ Tirnitz-Parker JE, Glanfield A, Olynyk JK, et al. Iron and hepatic carcinogenesis［J］. Crit Rev Oncog, 2013, 18(5): 391-407. ［4］ Brookes MJ, Boult J, Roberts K, et al. A role for Iron in Wnt signalling［J］. Oncogene, 2008, 27(7): 966-975. DOI: 10.1038/sj.onc.1210711. ［5］ Huang X. Iron overload and its association with cancer risk in humans: evidence for Iron as a carcinogenic metal［J］. Mutat Res, 2003, 533(1/2): 153-171. ［6］孙雪峰, 周道斌, 赵永强. EPO对铁调节蛋白Hepcidin表达影响的研究［J］. 中国实验血液学杂志, 2006, 14(4): 778-782. ［7］ Huang FW, Pinkus JL, Pinkus GS, et al. A mouse model of juvenile hemochromatosis［J］. J Clin Invest, 2005, 115(8): 2187-2191. DOI: 10.1172/JCI25049. ［8］ Wang RH, Li C, Xu X, et al. A role of SMAD4 in Iron metabolism through the positive regulation of hepcidin expression［J］. Cell Metab, 2005, 2(6): 399-409. DOI: 10.1016/j.cmet.2005.10.010. ［9］ Wu S, Zhang K, Lv C, et al. Nuclear factor-κB mediated lipopolysaccharide-induced mRNA expression of hepcidin in human peripheral blood leukocytes［J］. Innate Immun, 2012, 18(2): 318-324. DOI: 10.1177/1753425911405087. ［10］ Xia Y, Babitt JL, Sidis Y, et al. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin［J］. Blood, 2008, 111(10): 5195-5204. DOI: 10.1182/blood-2007-09-111567. ［11］ Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin［J］. Blood, 2005, 106(8): 2884-2889. DOI: 10.1182/blood-2005-05-1845. ［12］潘湘涛, 陆晔, 程旭, 等. 癌性贫血患者血清Hepcidin及炎症介质因子LPS和IL-6表达及其意义［J］. 中国实验诊断学, 2012, 16(1): 55-57. DOI: 10.3969/j.issn.10074287.2012.01.019 ［13］史玉娟, 潘湘涛. 癌性贫血患者血清BMP6和BMP4水平变化及其与Hepcidin和HJV的关系［J］. 现代检验医学杂志, 2014, 29(2): 41-43. DOI: 10.3969/j.issn.16717414.2014.02.012.

[1]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492.
[6]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185.
[9]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116.
[10]	Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86.
[11]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.
[12]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682.
[13]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635.
[14]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281.
[15]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun.Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer[J]. Journal of International Oncology, 2022, 49(12): 724-728.